 Harpoon Therapeutics Inc NASDAQ: HARP has announced interim data from the ongoing dose-escalation portion of a Phase 12a trial evaluating HPN424 in patients with metastatic castration-resistant prostate cancer mCRPC. Data were presented at the 2021 American Society of Clinical Oncology ASCO Annual Meeting. 